vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and PagerDuty, Inc. (PD). Click either name above to swap in a different company.
PagerDuty, Inc. is the larger business by last-quarter revenue ($124.5M vs $86.8M, roughly 1.4× IOVANCE BIOTHERAPEUTICS, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 4.7%). PagerDuty, Inc. produced more free cash flow last quarter ($24.1M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 5.9%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
PagerDuty, Inc. is an American cloud computing company specializing in a SaaS incident management platform for IT operations departments.
IOVA vs PD — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $124.5M |
| Net Profit | — | $161.6M |
| Gross Margin | 67.4% | 85.3% |
| Operating Margin | -84.7% | 6.5% |
| Net Margin | — | 129.7% |
| Revenue YoY | 17.7% | 4.7% |
| Net Profit YoY | — | 2827.7% |
| EPS (diluted) | — | $1.69 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | $124.5M | ||
| Q3 25 | $67.5M | $123.4M | ||
| Q2 25 | $60.0M | $119.8M | ||
| Q1 25 | $49.3M | $121.4M | ||
| Q4 24 | $73.7M | $118.9M | ||
| Q3 24 | $58.6M | $115.9M | ||
| Q2 24 | $31.1M | $111.2M | ||
| Q1 24 | $715.0K | $111.1M |
| Q4 25 | — | $161.6M | ||
| Q3 25 | $-91.3M | $9.6M | ||
| Q2 25 | $-111.7M | $-7.2M | ||
| Q1 25 | $-116.2M | $-8.8M | ||
| Q4 24 | — | $-5.9M | ||
| Q3 24 | $-83.5M | $-10.9M | ||
| Q2 24 | $-97.1M | $-17.1M | ||
| Q1 24 | $-113.0M | $-28.2M |
| Q4 25 | 67.4% | 85.3% | ||
| Q3 25 | 43.0% | 84.6% | ||
| Q2 25 | 5.5% | 84.0% | ||
| Q1 25 | -0.8% | 83.6% | ||
| Q4 24 | 68.7% | 83.0% | ||
| Q3 24 | 46.2% | 82.7% | ||
| Q2 24 | -0.8% | 82.6% | ||
| Q1 24 | — | 81.7% |
| Q4 25 | -84.7% | 6.5% | ||
| Q3 25 | -140.7% | 2.9% | ||
| Q2 25 | -189.8% | -8.6% | ||
| Q1 25 | -245.8% | -9.6% | ||
| Q4 24 | -117.5% | -8.7% | ||
| Q3 24 | -152.1% | -13.8% | ||
| Q2 24 | -327.6% | -19.5% | ||
| Q1 24 | -16464.6% | -30.1% |
| Q4 25 | — | 129.7% | ||
| Q3 25 | -135.3% | 7.8% | ||
| Q2 25 | -186.2% | -6.0% | ||
| Q1 25 | -235.5% | -7.2% | ||
| Q4 24 | — | -5.0% | ||
| Q3 24 | -142.7% | -9.4% | ||
| Q2 24 | -312.2% | -15.4% | ||
| Q1 24 | -15800.8% | -25.3% |
| Q4 25 | — | $1.69 | ||
| Q3 25 | — | $0.10 | ||
| Q2 25 | $-0.33 | $-0.07 | ||
| Q1 25 | $-0.36 | $-0.12 | ||
| Q4 24 | $-0.24 | $-0.07 | ||
| Q3 24 | $-0.28 | $-0.14 | ||
| Q2 24 | $-0.34 | $-0.26 | ||
| Q1 24 | $-0.42 | $-0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $547.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $698.6M | $320.5M |
| Total Assets | $913.2M | $1.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | $547.8M | ||
| Q3 25 | $300.8M | $567.9M | ||
| Q2 25 | $301.2M | $597.1M | ||
| Q1 25 | $359.7M | $570.8M | ||
| Q4 24 | $323.8M | $542.2M | ||
| Q3 24 | $397.5M | $599.3M | ||
| Q2 24 | $412.5M | $592.8M | ||
| Q1 24 | $356.2M | $571.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $484.5M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $489.5M |
| Q4 25 | $698.6M | $320.5M | ||
| Q3 25 | $702.3M | $180.7M | ||
| Q2 25 | $698.5M | $145.7M | ||
| Q1 25 | $767.9M | $129.8M | ||
| Q4 24 | $710.4M | $111.6M | ||
| Q3 24 | $773.5M | $164.7M | ||
| Q2 24 | $768.5M | $174.0M | ||
| Q1 24 | $680.0M | $171.6M |
| Q4 25 | $913.2M | $1.0B | ||
| Q3 25 | $904.9M | $891.5M | ||
| Q2 25 | $907.4M | $926.8M | ||
| Q1 25 | $966.7M | $927.3M | ||
| Q4 24 | $910.4M | $866.8M | ||
| Q3 24 | $991.1M | $916.0M | ||
| Q2 24 | $964.3M | $924.0M | ||
| Q1 24 | $869.8M | $925.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 3.73× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 2.85× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $24.8M |
| Free Cash FlowOCF − Capex | $-61.9M | $24.1M |
| FCF MarginFCF / Revenue | -71.3% | 19.3% |
| Capex IntensityCapex / Revenue | 10.7% | 0.6% |
| Cash ConversionOCF / Net Profit | — | 0.15× |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | $117.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | $24.8M | ||
| Q3 25 | $-78.7M | $34.0M | ||
| Q2 25 | $-67.4M | $30.7M | ||
| Q1 25 | $-103.7M | $31.4M | ||
| Q4 24 | $-73.3M | $22.1M | ||
| Q3 24 | $-59.0M | $35.8M | ||
| Q2 24 | $-98.4M | $28.6M | ||
| Q1 24 | $-122.3M | $22.2M |
| Q4 25 | $-61.9M | $24.1M | ||
| Q3 25 | $-89.5M | $33.1M | ||
| Q2 25 | $-74.9M | $30.2M | ||
| Q1 25 | $-109.9M | $30.3M | ||
| Q4 24 | $-77.5M | $21.5M | ||
| Q3 24 | $-61.3M | $35.1M | ||
| Q2 24 | $-98.9M | $28.2M | ||
| Q1 24 | $-126.5M | $21.2M |
| Q4 25 | -71.3% | 19.3% | ||
| Q3 25 | -132.7% | 26.8% | ||
| Q2 25 | -124.9% | 25.2% | ||
| Q1 25 | -222.8% | 24.9% | ||
| Q4 24 | -105.1% | 18.1% | ||
| Q3 24 | -104.6% | 30.3% | ||
| Q2 24 | -317.9% | 25.4% | ||
| Q1 24 | -17685.3% | 19.1% |
| Q4 25 | 10.7% | 0.6% | ||
| Q3 25 | 16.1% | 0.7% | ||
| Q2 25 | 12.4% | 0.4% | ||
| Q1 25 | 12.6% | 0.9% | ||
| Q4 24 | 5.7% | 0.5% | ||
| Q3 24 | 3.9% | 0.5% | ||
| Q2 24 | 1.4% | 0.4% | ||
| Q1 24 | 583.4% | 0.9% |
| Q4 25 | — | 0.15× | ||
| Q3 25 | — | 3.55× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
PD
| US | $88.8M | 71% |
| Non Us | $35.7M | 29% |
